Eli Lilly and Company beat EPS estimates 63% of the time across 19 reported quarters (12 beats, 7 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $7.47 | — | — | Miss |
| Q12026 FY2026 | $7.06 | $8.55 | +21.1% | Beat |
| Q42025 FY2025 | $6.99 | $7.54 | +7.9% | Beat |
| Q42024 FY2024 | $5.03 | $5.32 | +5.8% | Beat |
| Q42023 FY2023 | $2.22 | $2.49 | +12.2% | Beat |
| Q3 FY2023 | $-0.08 | $0.10 | +225.0% | Beat |
| Q2 FY2023 | $1.98 | $2.11 | +6.6% | Beat |
| Q1 FY2023 | $1.73 | $1.62 | -6.4% | Miss |
| Q42022 FY2022 | $1.78 | $2.09 | +17.4% | Beat |
| Q32022 FY2022 | $1.92 | $1.98 | +3.1% | Beat |
| Q22022 FY2022 | $1.69 | $1.25 | -26.0% | Miss |
| Q12022 FY2022 | $2.32 | $2.62 | +12.9% | Beat |
Back to LLY overview · LLY holders · LLY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.